SBH
ADMA icon

Segall Bryant & Hamill’s ADMA Biologics ADMA Stock Holding History

Segall Bryant & Hamill’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$219K Hold
24,280
– – ﹤0.01% 576
2025
Q4 		$443K Sell
24,280
-187,887
-89% -$3.17M 0.01% 556
2025
Q3 		$3.11M Sell
212,167
-65,566
-24% -$1.12M 0.04% 362
2025
Q2 		$5.06M Sell
277,733
-18,709
-6% -$382K 0.07% 313
2025
Q1 		$5.88M Sell
296,442
-9,910
-3% -$171K 0.09% 287
2024
Q4 		$5.25M Sell
306,352
-44,987
-13% -$846K 0.07% 325
2024
Q3 		$7.02M Sell
351,339
-99,936
-22% -$1.55M 0.1% 281
2024
Q2 		$5.05M Buy
+451,275
New +$3.79M 0.09% 293

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Segall Bryant & Hamill's ADMA Position: Q1 2026 in Review

Segall Bryant & Hamill held its ADMA Biologics (ADMA) position steady in Q1 2026 at 24,280 shares worth $219K. The position accounts for ﹤0.01% of the portfolio, ranked #576.

Segall Bryant & Hamill first reported a position in ADMA in Q2 2024 and has held it in 8 quarters since. The position peaked at $7.02M in Q3 2024. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Segall Bryant & Hamill held 24,280 shares of ADMA Biologics worth $219K as of Q1 2026.
  • Segall Bryant & Hamill left its ADMA Biologics share count unchanged in Q1 2026.
  • ADMA Biologics made up ﹤0.01% of Segall Bryant & Hamill's portfolio in Q1 2026, its #576 holding.
  • Segall Bryant & Hamill first reported a position in ADMA Biologics in Q2 2024 and has held it in 8 quarters since.
  • Segall Bryant & Hamill's ADMA Biologics position peaked at $7.02M in Q3 2024.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Segall Bryant & Hamill's 13F filing for Q1 2026, filed 15 May 2026.